Allogene Therapeutics, Inc. (ALLO)

Market Cap	450.97M
Revenue (ttm)	65,000
Net Income (ttm)	-293.56M
Shares Out	208.78M
EPS (ttm)	-1.82
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,052,271
Open	2.290
Previous Close	2.330
Day's Range	2.125 - 2.290
52-Week Range	2.125 - 6.050
Beta	0.86
Analysts	Buy
Price Target	10.51 (+386.57%)
Earnings Date	Jul 31, 2024

About ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 fo...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2018
• Employees: 232
• Stock Exchange: NASDAQ
• Ticker Symbol: ALLO

Financial Performance

In 2023, ALLO's revenue was $95,000, a decrease of -39.10% compared to the previous year's $156,000. Losses were -$327.27 million, -3.86% less than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for ALLO stock is "Buy." The 12-month stock price forecast is $10.51, which is an increase of 386.57% from the latest price.

Price Target

$10.51

(386.57% upside)

Analyst Consensus: Buy